Telmisartan/Hydrochlorothiazide
Is It Right for You?
A complete guide to Telmisartan/Hydrochlorothiazide — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Telmisartan/Hydrochlorothiazide?
Telmisartan/Hydrochlorothiazide is a fixed-dose combination antihypertensive tablet containing two complementary blood pressure-lowering agents: telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. It is available in multiple dose combinations — most commonly 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg — and is taken once daily.
This combination tablet is used when a single antihypertensive agent provides insufficient blood pressure control. The rationale for combining an ARB with a thiazide diuretic is that they have complementary and partly synergistic mechanisms: telmisartan lowers blood pressure by blocking the renin-angiotensin-aldosterone system (RAAS), while hydrochlorothiazide reduces blood volume through diuresis. Together, they produce greater blood pressure reduction than either component alone, with some evidence that the combination also partially counteracts each other's metabolic side effects.
Fixed-dose combination products improve medication adherence — patients taking a single pill are more likely to be compliant than those managing multiple tablets. Hypertension is the single most important modifiable risk factor for stroke, heart attack, and cardiovascular death, and effective blood pressure control is one of the most impactful interventions in preventive medicine.
Telmisartan/Hydrochlorothiazide is a prescription-only medication. A clinician must assess your blood pressure, cardiovascular risk, renal function, electrolytes, and medical history before prescribing.
What Conditions Is Telmisartan/Hydrochlorothiazide Used For?
Telmisartan/Hydrochlorothiazide is indicated for:
specifically for patients in whom blood pressure is not adequately controlled on a single antihypertensive agent, and where combination treatment with an ARB and a thiazide diuretic is clinically appropriate.
effective blood pressure control with this combination reduces the risk of stroke, myocardial infarction (heart attack), heart failure, and hypertensive kidney disease.
Both components of this combination require monitoring during treatment — telmisartan requires assessment of renal function and serum potassium, while hydrochlorothiazide requires monitoring of potassium, sodium, glucose, and uric acid levels. Regular blood tests and blood pressure reviews are an essential part of safe management.
How Does Telmisartan/Hydrochlorothiazide Work?
Telmisartan is an angiotensin II receptor blocker (ARB) that specifically and selectively blocks the AT1 receptor — the main receptor through which angiotensin II exerts its blood pressure-raising effects. Angiotensin II is a potent vasoconstrictor that also stimulates aldosterone release (causing sodium and water retention). By blocking the AT1 receptor, telmisartan prevents vasoconstriction, reduces aldosterone-mediated fluid retention, and lowers blood pressure. Telmisartan has the longest half-life of all ARBs (approximately 24 hours), supporting consistent 24-hour blood pressure control with once-daily dosing, including protection at the critical early morning period when cardiovascular events are most common.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule of the kidney, reducing the reabsorption of sodium and water and increasing their excretion in urine. This reduces circulating blood volume, cardiac preload, and systemic vascular resistance, resulting in blood pressure reduction. Thiazide diuretics are among the oldest and most evidence-based antihypertensives available.
The two mechanisms are complementary — the RAAS blockade by telmisartan counteracts the reactive RAAS activation that occurs with diuretic therapy, while the volume reduction from hydrochlorothiazide addresses the fluid retention that can limit the effect of RAAS blockers alone. This synergy is well established and clinically validated.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Take once daily at the same time each day, with or without food. Consistent daily timing improves blood pressure control throughout the 24-hour period.
Swallow tablets whole with a glass of water. Do not crush unless alternative formulations are available.
Telmisartan/HCT is best taken in the morning in most patients, as the diuretic effect of hydrochlorothiazide can cause frequent urination — taking it in the evening may disrupt sleep.
Do not take potassium supplements or potassium-containing salt substitutes without clinician guidance. ARBs raise potassium levels (hyperkalaemia), and supplementation can cause dangerous elevations.
Stay well hydrated, particularly in hot weather, during exercise, or during illness with vomiting or diarrhoea, as dehydration can cause excessive blood pressure falls (hypotension) and impair kidney function.
Do not stop this medication suddenly without discussing with your clinician — blood pressure can rebound and increase cardiovascular risk.
Side Effects of Telmisartan/Hydrochlorothiazide
Common side effects include dizziness or light-headedness, headache, fatigue, increased urination, nausea, and gastrointestinal discomfort.
- Dizziness or light-headedness (particularly on standing)
- Headache
- Fatigue
- Increased urination
- Nausea or gastrointestinal discomfort
- Hyperkalaemia — muscle weakness, palpitations, cardiac arrhythmias; risk with ARBs, especially in renal impairment.
Both components of this combination can affect kidney function and electrolyte balance. Renal function and serum potassium should be measured before starting treatment and monitored regularly.
Drug Interactions
Telmisartan/Hydrochlorothiazide may interact with other Renin-Angiotensin System agents, lithium, and NSAIDs. Always inform your clinician about all medications you are taking.
Dual blockade of the RAAS significantly increases risk of hyperkalaemia, hypotension, and acute kidney injury. Concurrent use is generally contraindicated, particularly in diabetic patients.
Both ARBs and thiazides can increase lithium plasma levels to toxic concentrations. Concurrent use requires very close monitoring of lithium levels.
Contraindicated in the second and third trimesters. Causes foetal renal dysgenesis, oligohydramnios, limb contractures, and death.
Reduce the antihypertensive effect of telmisartan and significantly increase risk of acute kidney injury, particularly in elderly, dehydrated, or renally impaired patients. Avoid regular concurrent use.
Important Warnings
Telmisartan is contraindicated in the second and third trimesters of pregnancy and should be avoided in the first trimester. ARBs cause foetal renal damage, oligohydramnios, limb contractures, and death. Any woman of childbearing potential should use effective contraception and discontinue telmisartan as soon as pregnancy is confirmed.
Although angioedema is more commonly associated with ACE inhibitors, cases have been reported with ARBs. If swelling of the face, lips, tongue, or throat occurs, discontinue immediately and seek emergency care.
Telmisartan must be used with caution in patients with significant renal impairment and is generally contraindicated in severe renal impairment. Patients with bilateral renal artery stenosis or stenosis in a single functioning kidney are at high risk of acute kidney injury.
Hydrochlorothiazide can cause hypokalaemia, hyponatraemia, and hypomagnesaemia. These electrolyte disturbances increase the risk of cardiac arrhythmias and can be clinically significant in patients taking digoxin or antiarrhythmic medications.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Telmisartan/Hydrochlorothiazide FAQs
Yes, via a telehealth consultation. Initiating or adjusting antihypertensive combination therapy requires blood pressure assessment and a review of renal function and electrolytes. Your clinician will need access to recent blood test results or may recommend these before prescribing.
Combination therapy is recommended when a single antihypertensive agent is not achieving target blood pressure. Rather than increasing one drug to higher doses (which often brings diminishing returns and more side effects), combining two agents at moderate doses is both more effective and better tolerated.
The diuretic effect of hydrochlorothiazide is relatively mild at the doses used in this combination. Most patients notice a modest increase in urination, particularly in the first few weeks. Taking the tablet in the morning minimises disruption to sleep.
Regular use of NSAIDs such as ibuprofen is not recommended while taking telmisartan/HCT. NSAIDs reduce the effectiveness of both components and can impair kidney function significantly, particularly in older patients or those with pre-existing kidney issues. Paracetamol is generally a safer choice for pain relief in patients on antihypertensives.
Renal function and electrolytes should be checked before starting and again at 1–3 months after initiation, then annually in stable patients. More frequent monitoring is required if you have kidney disease, are elderly, take other medications that affect electrolytes, or experience any illness causing vomiting or diarrhoea.